Skip to content

Jula Inrig, EVP, Head of R&D & CMO at Travere Therapeutics, sold TVTX on Sep 15, 2026

Data as of Oct 16

▼ SELL$102K1,600 shares at $63.69Jula Inrig EVP, Head of R&D & CMOTVTX Travere Therapeutics, Inc.
Watch TVTX
Traded
Sep 15, 2026
Disclosed
Sep 17, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Jula Inrig, EVP, Head of R&D & CMO at Travere Therapeutics, sold TVTX on Sep 15, 2026TRADEDDISCLOSED
TVTXSimilar stocks (XLV — its sector index fund), rebased to TVTX's price on the disclosure day
TVTX since disclosure
−23.4%
after the sale
Similar stocks (XLV) since disclosure
+4.7%
XLV — its sector index fund

Change in closing price from Sep 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLJula Inrig EVP, Head of R&D & CMOTVTX Travere Therapeutics, Inc.$1.6Mdisclosed Sep 17 · filed 2 days after the trade
  2. ▼ SELLJula Inrig EVP, Head of R&D & CMOTVTX Travere Therapeutics, Inc.$1.1Mdisclosed Sep 17 · filed 2 days after the trade
  3. ▼ SELLJula Inrig EVP, Head of R&D & CMOTVTX Travere Therapeutics, Inc.$26.1Kdisclosed Sep 17 · filed 2 days after the trade

See every trade on TVTX →